{"abstract":"The Food and Drug Administration (FDA) is clarifying that the currently approved indications for doxycycline and penicillin G procaine drug products include use in cases of inhalational exposure to Bacillus anthracis (the bacterium that causes anthrax). We also are providing dosing regimens that we have determined are appropriate for these products for this use. We encourage the submission of supplemental new drug applications (labeling supplements) to add the dosage information to the labeling of currently marketed drug products.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2001/11/02/01-27493.html","cfr_references":[],"citation":"66 FR 55679","comment_url":null,"comments_close_on":null,"correction_of":null,"corrections":[],"dates":null,"disposition_notes":null,"docket_ids":["Docket No. 01N-0494"],"dockets":[],"document_number":"01-27493","effective_on":null,"end_page":55682,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2001/11/02/01-27493.xml","html_url":"https://www.federalregister.gov/documents/2001/11/02/01-27493/prescription-drug-products-doxycycline-and-penicillin-g-procaine-administration-for-inhalational","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/01-27493?publication_date=2001-11-02","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2001-11-02/01-27493/mods.xml","not_received_for_publication":null,"page_length":4,"page_views":{"count":380,"last_updated":"2026-06-23 18:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2001-11-02/pdf/01-27493.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":null,"publication_date":"2001-11-02","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2001/11/02/01-27493.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":55679,"subtype":null,"title":"Prescription Drug Products; Doxycycline and Penicillin G Procaine Administration for Inhalational Anthrax (Post-Exposure)","toc_doc":"Anthrax inhalation exposure; doxycycline and penicillin G procaine administration","toc_subject":"Human drugs:","topics":[],"type":"Notice","volume":66}